Print E-mail

Alitair Announces Notice of Patent Allowance for Safer Formulation of Benzonatate

MORRISTOWN, New Jersey – September 26, 2012 – Alitair Pharmaceuticals, Inc., today announced that it received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for its ion exchange resin formulation of benzonatate. The patent includes specific claims for reducing or eliminating the choking hazard associated with conventional liquid formulations of benzonatate.

"Benzonatate is the only non-narcotic prescription cough product available today, but in its current form, it has a significant choking hazard if a patient bites into the liquid-filled gel cap. Our oral solid ion exchange resin formulation has been shown to reduce or eliminate the choking hazard," stated Alitair President and CEO, William W. Howard, Ph.D. "Our proprietary technology allows us to bind benzonatate to a resin particle, which represents a completely novel formulation approach and resolves this significant safety issue."

"This Notice of Allowance marks an important milestone in our benzonatate product development strategy and may be the key to benzonatate becoming a successful Rx-to-OTC switch candidate," continued Howard. "This is highly desirable, because the need for safe and effective non-narcotic cough formulations is great, especially when you consider how widespread dextromethorphan abuse has become."

Alitair is filing a second patent related to its benzonatate product candidate, which will further strengthen the Company’s intellectual property portfolio. Alitair is actively seeking a partner for its benzonatate product candidate and estimates annual sales between $75 and $100 million for a prescription or OTC benzonatate product using its proprietary ion exchange resin technology.

About Alitair Pharmaceuticals:
Alitair Pharmaceuticals, Inc., discovers, invents, and develops medicines for the treatment of respiratory illnesses. Alitair has out-licensed two prescription cough candidates that use its proprietary ion exchange resin technology (REA™), and other product candidates are available for out-licensing. Additional information about Alitair is available on the Alitair website at www.alitair.com.

###

Source: Alitair Pharmaceuticals, Inc.
www.alitair.com

Contact: Faith Pomeroy-Ward
Vice President, Corporate Development
817-490-5152 | This e-mail address is being protected from spambots. You need JavaScript enabled to view it

 
Solution Managers